Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin-D adds asthma safety labeling; Hoechst and Schering settle in Claritin ad dispute.

Executive Summary

SCHERING-PLOUGH CLARITIN-D ADDS ASTHMA SAFETY DATA TO LABELING Feb. 5: the company announced that it is updating the Claritin-D label with information regarding the safety of its loratadine/pseudoephedrine product in seasonal allergic rhinitis patients with concomitant asthma. Prescribing information for Claritin-D now lists results of a study in patients with asthma and states: "This supports the safety of administering Claritin-D to seasonal allergic rhinitis patients with asthma." In the six-week, placebo-controlled study, patients with rhinitis and mild-to-moderate asthma had improvements in allergy symptoms with no decrease in pulmonary function, Schering reported.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029748

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel